Press

News Reports  |   Press Releases  |   Videos  |   Archived Press

 

News Reports

TScan Co-founders Lea Hachigian and Tomasz Kula named to Forbes 30 Under 30 List
Forbes: December 3, 2019
Read More

Millendo Therapeutics: A Forgotten Biotech With Strong Potential
Seeking Alpha: November 25, 2019
Read More

Human Nature: Single-Cell Genomics Immunitas Launches with a Series A
BioWorld: November 22, 2019
Read More

Immunitas Snags $39M to Bring New I-O Approach to the Clinic
Fierce Biotech: November 21, 2019
Read More

Immunitas Therapeutics Gets $39 Million for Cancer Drug Discovery
Wall Street Journal: November 21, 2019
Read More

Longwood Launches Immunitas with $39M and Single-Cell Genomics Platform
BioCentury: November 21, 2019
Read More

Novartis, Bayer, Longwood Back Genomics Startup to Speed Search for Immunotherapy Targets
Endpoints: November 21, 2019
Read More

Biotech Startup Werewolf Therapeutics Hunts Down $56 Million
Wall Street Journal: November 20, 2019
Read More

MPM and Longwood-backed Werewolf Therapeutics Grabs $56 Million to Take Tumors by Night
Endpoints: November 20, 2019
Read More

FDA Approves Alnylam Drug for Rare Genetic Disorder
STAT: November, 20, 2019
Read More

FDA Approves Acceleron's Blood Disorder Drug ahead of Schedule
Boston Business Journal: November 8, 2019
Read More

Rotational Fraction Resection for Submental Contouring
Dermatology Times: August 27, 2019
Read More

CELL: T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes
CELL: Volume 178, ISSUE 4, P1016-1028.e13, August 08, 2019
Read More

Novartis backs Harvard spinout's quest to build TCR repository in $48M round
Endpoints News: July 24, 2019
Read More

TScan Lands $48M for Better, Safer T-Cell Receptor Cancer Therapies
Xconomy: July 24, 2019
Read More

TScan Therapeutics uncloaks with $48M to unleash new TCR targets
FierceBiotech: July 24, 2019
Read More

Bayer, Longwood Back Star Researcher's Deep Dive into the Tumor Microenvironment for New I/O Targets
Endpoints News: July 17, 2019
Read More

New Drug Trial in Auckland Could Make Life Easier for Autistic Children
New Zealand Herald: May 17, 2019
Read More

Looking Beyond Cancer, Twentyeight-Seven Therapeutics Bumps up Series A to $82M+
FierceBiotech: May 10, 2019
Read More

Newly Discovered Link Between the Appendix and Parkinson’s Disease Could Point to the Way to Treatments
FierceBiotech, October 31, 2018
Read More

A promising new minimally invasive procedure for skin contouring
Dermatology Times: October 17, 2018
Read More

GlaxoSmithKline Helps Immunometabolism Startup Sitryx to $30M Round
Fierce Biotech: October 8, 2018
Read More

Biotech Firm Grail Takes the First Steps in its Quest for a Blood Test for Cancer
Forbes: June 2, 2018
Read More

Axial Co-Founder Sarkis Mazmanian: What's Living in You?
Discover how a world of microbes living in and on you can make you sick-and keep you healthy. PBS, NOVA: May 2, 2018
Watch Nova

One Scientist’s Marathon Quest for the Exercise Pill
Bloomberg Businessweek: October 17, 2017
Read More

Silicon Valley Startup Grail Sees Hope for Cancer Blood Test
Bloomberg News: August 9, 2017
Read More

Rich Aldrich Honored as One of the 100 Most Influential Visionaries in Biotech
Scientific American Worldview: The Visionaries who Continue to Reshape Biotechnology – and the World
Read More

 

Press Releases

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests
Read More

PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy
Read More

Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA
Read More

Renovia Announces FDA 510(k) Clearance of Next-Generation leva® Pelvic Digital Therapeutic
Read More

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform
Read More

With Cell-By-Cell Take on Drug Discovery, Immunitas Debuts With $39M
Read More

Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Read More

Recros Medica Closes $14 Million Series A Financing
Read More

Axial Biotherapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial Evaluating AB-2004 in Patients with Autism Spectrum Disorder
Read More

Bicycle Announces First Patient Dosed in Phase I/II Trial for Patients with Advanced Solid Tumors
Read More

KalVista Provides Business Update; Phase 2 Clinical Trial in HAE Expected to Complete Enrollment in 2019 with Data in 2020; Phase 2 Clinical Trial Data in DME Expected This Quarter
Read More

Millendo Reports Third Quarter 2019 Operating and Financial Results; Livoletide pivotal study in PWS completed recruitment and is on track to report topline results in 1H20; Nevanimibe Phase 2b study in CAH continues recruitment, topline results expected
Read More

Millendo Completes Patient Recruitment for Pivotal Study of Livoletide in Prader-Willi Syndrome
Read More

Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update
Read More

FDA Grants Fast Track Designation for the Development of Mitobridge's ASP1128 for Patients at Risk for Acute Kidney Injury
Read More

PTC Therapeutics Announces Results from Gene Therapy Treatment Demonstrating Sustained Improvements
Read More

Verastem Announces COPIKTRA Presentations
Read More

Bicycle Therapeutics Expands Neuroscience Collaborations to Include Oxford University’s Oxford Drug Discovery Institute
Read More

Axial Biotherapeutics Presents Preclinical Data on Microbiome-Derived Metabolites Associated with Autism Spectrum Disorder
Read More

Pyxis Oncology Appoints Pharmaceutical Industry Veteran Ronald Herbst, PhD, as Chief Scientific Officer
Read More

Bicycle Therapeutics to Present New Translational and Preclinical Data
Read More

PTC Therapeutics Establishes Strategic Collaboration with Aldevron
Read More

Calithera Completes Enrollment in Mid-Stage RCC Study
Read

Verastem Announces Dosing of First Patient in Japanese Bridging Study
Read More

PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
Read More

Dana-Farber Study Confirms Accuracy of GRAIL's Blood Test for Cancer
Read More

Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors
Read More

KalVista Pharmaceuticals Reports Fiscal First Quarter Results
Read More

Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence
Read More

TScan Therapeutics Announces Pioneering Publication in Scientific Journal Cell Describing New Methods to Identify Targets for T Cell Receptor Immunotherapy
Read More

Millendo Therapeutics Reports Second Quarter 2019 Operating and Financial Results
Read More

Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update
Read More

Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
Read More

Verastem Oncology Signs an Exclusive License Agreement with Sanofi
Read More

TScan Therapeutics Formed to Overcome Challenges of Current Immunotherapies with Novel TCR Discovery Platform and $48 Million in Funding
Read More

In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris
Read More

Pyxis Oncology Founded by Longwood Fund with Financing Led by Bayer
Read More

Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder
Read More

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
Read More

Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib
Read More

Pulmocide Announces Nature Research Publication Showing PC945 in Combination with Standard Antifungal Treatment Causes a Synergistic Effect Against Aspergillus Fumigatus
Read More

Bicycle Therapeutics Announces Positive Topline Results from Oxurion’s Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
Read More

PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
Read More

Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis
Read More

Calithera Achieves Positive Topline Results in Randomized Phase 2 Study in Renal Cell Carcinoma
Read More

Colorescience Announces US Patent for Total Eye 3-in-1 Renewal Therapy SPF 35
Read More

PTC Receives FDA Approval for the Expansion of the EMFLAZA Labeling to Include Patients 2-5 Years of Age
Read More

GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer
Read More

GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study
Read More

Axial Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse Models
Read More

Bicycle Therapeutics Announces Pricing of Initial Public Offering
Read More

KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
Read More

Recros Medica Announces Positive 90-Day Results from CONFORM Study
Read More

Pulmocide Presents Clinical Update from Promising Antifungal Program at 2019 Respiratory Innovation Summit
Read More

ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio
Read More

GRAIL Announces Promising New Data with Early Detection Blood Test to be Presented at ASCO
Read More

Verastem to Present New COPIKTRA Dose Modification Data from Patients Treated in the Phase 3 DUO Study
Read More

GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation
Read More

Verastem Reports First Quarter 2019 Financial Results, $1.7M in Net Product Revenues
Read More

FDA Accepts Recros Medica De Novo Submission for Nuvellus Focal Contouring System
Read More

Bicycle Therapeutics Enters Neuroscience Arena through Collaboration with Dementia Discovery Fund
Read More

GRAIL Licenses Nasopharyngeal Cancer Early Detection Technology to TAKE2
Read More

Axial Biotherapeutics Releases New Preclinical Data from AB-2004 Program Demonstrating Reduction of Microbiome-Derived Metabolites in Mouse Models with Autism Spectrum Disorder
Read More

Colorescience Reveals Clinical Advancements to Reduce Redness Associated with Rosacea
Read More

Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I Trial for the Treatment of Diabetic Macular Edema
Read More

Channel Medsystems Receives U.S. FDA Approval of the Cerene Cryotherapy Device
Read More

Millendo Reports Full Year 2018 Operating and Financial Results
Read More

ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients
Read More

Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Read More

Millendo Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome
Read More

KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth
Read More

PTC to Expand Product Portfolio in Latin America with WAYLIVRA™
Read More

Axial Biotherapeutics Raises $25 Million in Series B Financing
Read More

KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Read More

Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
Read More

Verastem Oncology Announces Key Management Appointments
Read More

Bicycle Therapeutics Strengthens Executive Team with Key Changes
Read More

Bicycle Therapeutics Announces Publication of Its Paper Demonstrating Utility of Bicycles™ as Imaging Agents
Read More

Verastem Announces Publication of Phase 2 Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology
Read More

Bicycle Therapeutics Awarded SBRI Contract to Address Antimicrobial Resistance in Humans
Read More

ArcherDX Announces Broad-Based Strategic Collaboration with Genosity
Read More

Calithera Completes Patient Enrollment in Randomized Phase 2 Trial in Renal Cell Carcinoma
Read More

KalVista Appoints Brian J. G. Pereira, MD to Board of Directors
Read More

PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders
Read More

ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
Read More

Renovia Appoints John A. Fallon, M.D. to Its Board of Directors
Read More

ArcherDX's Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by FDA
Read More

Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline
Read More

KalVista Pharmaceuticals Provides Development Update and 2019 Clinical Plans
Read More

Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress
Read More

Recros Medica's Rotational Fractional Resection Hits the Sweet Spot for a More Defined Neckline
Read More

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection
Read More

KalVista Pharmaceuticals Provides Clinical Update on KVD900
Read More

Renovia Launches a Multi-Center RCT to Study Next-Generation leva® Pelvic Digital Therapeutic System for UI
Read More

Sygnature Discovery & Sitryx Therapeutics Enter Drug Discovery Deal
Read More

Verastem Oncology Reports Third Quarter 2018 Financial Results
Read More

Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy
Read More

Axial Biotherapeutics Strengthens Senior Management Team with Appointment of Jeff Young as Chief Financial Officer
Read More

GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at ESMO
Read More

Recros Medica Showcases Interim Data on Rotational Fractional Resection Technology
Read More

New Biopharmaceutical Company Sitryx Launches with $30 Million Fundraising to Develop Disease Modifying Therapeutics in Immunometabolism
Read More

Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration
Read More

GRAIL Announces Appointment of Renée Galá as Chief Financial Officer
Read More

Bicycle Therapeutics’ Founder Sir Gregory Winter Awarded Nobel Prize in Chemistry
Read More

Verastem Oncology Signs Exclusive License Agreement for the Development and Commercialization of COPIKTRA™ (duvelisib) in China
Read More

KalVista Pharmaceuticals Reports Fiscal First Quarter Results
Read More

IlluminOss Medical Receives Clearance to Expand Clinical Indications in the US
Read More

Astellas Completes Acquisition of Mitobridge, Inc.
Read More

Recros Medica Closes $9M Financing, Strengthens Board
Read More

Millendo Acquires Alizé Pharma SAS to Expand Orphan Endocrinology Pipeline
Read More

Millendo Therapeutics Announces Positive Phase 2 Results in Classic Congenital Adrenal Hyperplasia, Receives FDA Orphan Drug Designation
Read More

Flex Pharma Announces Positive Phase 2 ALS Results
Read More

KalVista Pharmaceuticals Announces Collaboration with Merck
Read More

Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Read More

Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia and Sickle Cell Disease
Read More

Bicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
Read More

GRAIL Initiates the STRIVE Study to Advance Development of Blood Tests to Detect Cancer Early
Read More

 

Videos